Refine by
Vaccine Drug Candidate Articles & Analysis
22 articles found
Tissue cross-reactivity studies play an essential role in the understanding of immune responses, particularly in the context of autoimmunity, transplant rejection, and vaccine development. These studies aim to identify whether antibodies or T cells generated against a particular antigen react with similar proteins found in different tissues, which can lead to unintended effects and complications. ...
What are Adjuvants? Adjuvants, also known as immunomodulators or immune enhancers, are an additive to vaccines. Adjuvants are non-specific immune enhancers that enhance or alter the type of immune response to an antigen. Adjuvants can help antigens induce long-term effective specific immune responses in vivo, leading to higher vaccine efficacy and prolonged protection from immune responses. ...
As of January 1, 2023, global vaccine development includes a total of 966 vaccine candidates, of which 23% (220) are traditional inactivated or attenuated vaccines. Advances in molecular technology have facilitated the development of other platforms, such as recombinant protein vaccines, nucleic acid vaccines, and viral vector vaccines, which have further diversified global vaccine development. ...
Interestingly, an investigational tuberculosis vaccine candidate was found to be significantly effective against the disease in the trial phase conducted in Kenya and Zambia, making it a potential vaccine in the future. ...
Abera’s vaccine delivery platform works as a plug-and-play system where known or novel antigens can be engineered onto our delivery platform to create effective, multivalent vaccines that are cost-effective and fast to produce. We actively work together with academia and industry to enable the use of our vaccine delivery platform in design and development of new vaccines. Many of these ...
MADISON, Wis., Sept. 7, 2022 /PRNewswire/ — FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, today announced the completion of enrollment of the first cohort in an age de-escalation clinical trial of M2SR (M2 Deficient Single Replication) live virus vaccine, the company’s investigational supra-seasonal intranasal ...
Study to be conducted at two leading research institutions in the U.K. Results will inform protocol design of Phase 1/2 clinical trial of Company's lead HSV-2 therapeutic vaccine candidate WOBURN, Mass. and OXFORD, England, Aug. 15, 2022 /PRNewswire/ -- Rational Vaccines, a company focused on revolutionizing the treatment and prevention of herpes to eradicate the disease, today announced the ...
Rational Vaccines' experimental vaccine candidate for herpes simplex virus type 2 (HSV-2), the primary cause of genital herpes, is showing promise in preclinical studies. ...
RVx201 Herpes Vaccine Description 2022 RVx201 is a first-in-human herpes simplex virus type 2 (HSV-2) live-attenuated therapeutic vaccine modified to be interferon sensitive that destroys the ability of the virus to inhibit immune responses. Produced by Rational Vaccines, Inc., the technology is based on the pioneering research of the late Dr. William Halford, who dedicated over 25 years to ...
His laboratory also studies the interaction of antibodies and viruses, providing clues for the design of antiviral drugs and vaccines for these two virus families. The researchers explain that Nipah virus and Hendra virus enter cells by binding and fusing glycoproteins that work together. ...
Jonathan “Jake” Kurtis was riding a night train from Nairobi to Mombasa when he first began to feel sick. Then a 20-year-old Brown junior, Kurtis had gone to the restaurant car for a curry and stayed up late drinking beer with some Americans he’d met. By the time he got back to his sleeper car, he had a vicious headache. “I thought God had visited upon me a righteous ...
Data published in the Journal of Infectious Diseases demonstrate that M2SR can protect against a multi-seasonal, seven-year drifted influenza strain – MADISON, Wis., Aug. 2, 2021 /PRNewswire/ — FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, today announced the publication of results from its Phase 2 human challenge ...
LONDON, June 28, 2021 (GLOBE NEWSWIRE) – Treos Bio Limited (“Treos”), a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision off-the-shelf and personalized peptide cancer immunotherapies, today announced the publication of a peer-reviewed article titled “A Peptide Vaccine Candidate Tailored to Individuals’ Genetics ...
Study is the Company’s first trial evaluating ability of M2SR and the current licensed standard of care to protect against drifted virus strains, and its second study in older adults, a population most vulnerable to mortality from flu – Safety and immunogenicity study expected to begin in Q2 2022 – MADISON, Wis., July 1, 2021 /PRNewswire/ — FluGen, Inc., a clinical-stage ...
The study demonstrated that, following a vaccination using Micron’s technology, the immune response was as strong, or stronger, than vaccination by intramuscular injection. In addition, while the safety profile for Micron’s technology and intramuscular vaccination were similar, a survey showed a strong preference for Micron’s ...
A gold rush is on to find a vaccine for COVID-19. According to the World Health Association (WHO) in early May, there are more than 100 projects around the world centered on the development of a vaccine for the coronavirus. Eight candidate vaccines are already being tested in people in clinical trials. Once an effective vaccine (or vaccines) has been identified, it will need to be produced ...
MADISON, Wis.–(BUSINESS WIRE)–An international collaboration of virologists at the University of Wisconsin–Madison and the vaccine companies FluGen and Bharat Biotech has begun the development and testing of a unique vaccine against COVID-19 called CoroFlu. UW–Madison, FluGen, Bharat Biotech to develop CoroFlu, a coronavirus vaccineTweet this CoroFlu will build on the ...
When lives are at stake, there is no time to lose. With researchers ramping up efforts to develop a COVID-19 vaccine, progress has been achieved at unprecedented speed. In just two months, the first vaccine candidate entered clinical trials. A first in history. While vaccine development is advancing by leaps and bounds, it is high time to put in similar efforts to prepare for the next step. Now ...
“With the spray drying technology, we have been able to achieve positive outcomes on our flagship vaccine candidate and are planning to extend the technology to other antigens and biopharmaceuticals as well.” Customer name Dr. Nitin Saigal, Formulation Scientist Company / Institution MSD Wellcome Trust Hilleman Laboratories, India Product lines Spray Drying and Encapsulation ...
ByBUCHI
This protection was unmatched by a relevant glycoprotein subunit vaccine. Efficacy of the live-attenuated vaccine involved a T-dependent humoral immune response and complement C3 but not Fcy-receptor 3 or interferon-a/p signaling. ...